Compass Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 32
- Market Cap
- $173.3M
- Introduction
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Conditions
- Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaTriple Negative Breast CancerHodgkin LymphomaMalignant Melanoma
- Interventions
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 55
- Registration Number
- NCT06150664
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸D&H Cancer Research Center, Margate, Florida, United States
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal CancerColon CancerRectal Cancer
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 49
- Registration Number
- NCT05513742
- Locations
- 🇺🇸
Genesis Cancer and Blood Institute, Hot Springs, Arkansas, United States
🇺🇸Florida Cancer Specialists & Research Institute - South, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists & Research Institute - North, Saint Petersburg, Florida, United States
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
- Conditions
- Ampullary CancerGall Bladder CancerBiliary Tract CancerCholangiocarcinoma
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT05506943
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
- Conditions
- Non-small Cell Lung CancerHead and Neck CancerLocally Advanced Solid TumorMelanomaMetastatic CancerSmall Cell Lung CancerMesothelioma
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Compass Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT03881488
- Locations
- 🇺🇸
Ocala Oncology Center, Ocala, Florida, United States
🇺🇸Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
News
Commit Biologics Forms Scientific Advisory Board to Advance Complement-Based Cancer and Autoimmune Therapies
Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.
Compass Therapeutics Advances Pipeline with New Bispecific Antibody Candidate
Compass Therapeutics is set to release Phase 2/3 data for tovecimig in biliary tract cancer by the end of Q1 2025, marking a key milestone.
Compass Therapeutics' CTX-471 Shows Promise with NCAM Biomarker Correlation in Advanced Malignancies
• Compass Therapeutics presented data at SITC showing a significant correlation between NCAM expression and patient response to CTX-471 monotherapy. • The Phase 1 trial data suggests NCAM enriches activated NK cells in the tumor microenvironment, potentially enhancing CTX-471's efficacy. • A Phase 2 monotherapy basket study is planned to further evaluate CTX-471 in patients with NCAM-expressing tumors who have progressed on PD-1/PD-L1 inhibitors. • The findings support the potential use of NCAM as a predictive biomarker for patient selection in future CTX-471 clinical trials.